N
Nevena Damjanov
Researcher at University of Pennsylvania
Publications - 42
Citations - 2644
Nevena Damjanov is an academic researcher from University of Pennsylvania. The author has contributed to research in topics: Cancer & Colorectal cancer. The author has an hindex of 16, co-authored 34 publications receiving 1799 citations.
Papers
More filters
Journal ArticleDOI
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X. Zhu,Richard S. Finn,Julien Edeline,Stéphane Cattan,Sadahisa Ogasawara,Daniel H. Palmer,Chris Verslype,Vittorina Zagonel,Laetitia Fartoux,Arndt Vogel,Debashis Sarker,Gontran Verset,Stephen L. Chan,Jennifer J. Knox,Bruno Daniele,Andrea L. Webber,Scot Ebbinghaus,Junshui Ma,Abby B. Siegel,Ann-Lii Cheng,Masatoshi Kudo,Angela Tatiana Alistar,Jamil Asselah,Jean-Frédéric Blanc,Ivan Borbath,Timothy Cannon,Ki Chung,Allen Lee Cohn,David Cosgrove,Nevena Damjanov,Mukul Gupta,Yoshivasu Karino,Mark Karwal,Andreas Kaubisch,Robin Kate Kelley,Jena-Luc Van Laethem,Timothy Larson,James Lee,Daneng Li,Atisha Manhas,Gulam Abbas Manji,Kazushi Numata,Benjamin M. Parsons,Andrew Scott Paulson,Carmine Pinto,Robert A. Ramirez,Suresh Ratnam,Magnus Rizell,Olivier Rosmorduc,Yvonne Sada,Yutaka Sasaki,Per I Stal,Simone I. Strasser,Joerg Trojan,Gina M. Vaccaro,Hans Van Vlierberghe,Alan Weiss,Karl-Heinz Weiss,Tatsuya Yamashita +58 more
TL;DR: Pembrolizumab was effective and tolerable in patients with advanced hepatocellular carcinoma who had previously been treated with sorafenib and is undergoing further assessment in two phase 3, randomised trials as a second-line treatment.
Journal ArticleDOI
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa,Eric Assenat,Markus Peck-Radosavljevic,Marc Pracht,Vittorina Zagonel,Philippe Mathurin,Elena Rota Caremoli,Camillo Porta,Bruno Daniele,Luigi Bolondi,Vincenzo Mazzaferro,William P. Harris,Nevena Damjanov,Davide Pastorelli,Maria Reig,Jennifer J. Knox,Francesca Negri,Jörg Trojan,Carlos López López,Nicola Personeni,Thomas Decaens,Thomas Decaens,Marie Dupuy,W. Sieghart,Giovanni Abbadessa,Brian Schwartz,Maria Lamar,Terri Goldberg,Dale Shuster,Armando Santoro,Jordi Bruix +30 more
TL;DR: Although this METIV-HCC trial was negative, the study shows the feasibility of doing integral tissue biomarker studies in patients with advanced hepatocellular carcinoma, and additional randomised studies are needed to establish whether MET inhibition could be a potential therapy for some subsets of patients withadvanced hepato cell carcinoma.
Journal ArticleDOI
Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer
Helen J. Ross,George R. Blumenschein,Joseph Aisner,Nevena Damjanov,Afshin Dowlati,Jennifer Garst,James R. Rigas,Michael Smylie,Habib Hassani,Kimberly E. Allen,Lance Leopold,Tal Zaks,Frances A. Shepherd +12 more
TL;DR: Lapatinib monotherapy did not induce a significant number of tumor regressions in NSCLC and was well tolerated, with no notable difference in toxicity between treatment groups.
Journal ArticleDOI
A phase II trial of gemcitabine, irinotecan and panitumumab in advanced cholangiocarcinoma
Davendra Sohal,K. Mykulowycz,Takeshi Uehara,Ursina R. Teitelbaum,Nevena Damjanov,Bruce J. Giantonio,Mary Carberry,Paul Wissel,Mona Jacobs-Small,Peter O'Dwyer,Antonia R. Sepulveda,Weijing Sun +11 more
TL;DR: This study showed encouraging efficacy of this regimen with good tolerability and suggested that chemotherapy combinations may be superior to single agents in biliary tract cancer.
Journal ArticleDOI
Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Neutropenia during Phase I Development of Liposome-Entrapped Paclitaxel
Gerald J. Fetterly,Thaddeus H. Grasela,Jeffrey W. Sherman,Jeanne L. Dul,Amy Y. Grahn,Diane Lecomte,Jill Fiedler-Kelly,Nevena Damjanov,Mayer Fishman,Michael P. Kane,Eric H. Rubin,Antoinette R. Tan +11 more
TL;DR: Modeling and simulation studies predict that 325 mg/m2 LEP-ETU q3w provides acceptable neutropenic events relative to those observed at 175 mg/ m2 Taxol q3m and may offer an improved therapeutic index.